Get the Stockscreener App
14.63
0.95%
-0.14
After Hours:
14.63
Tandem Diabetes Care Inc stock is traded at $14.63, with a volume of 1.41M.
It is down -0.95% in the last 24 hours and down -27.65% over the past month.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.
See More
Previous Close:
$14.77
Open:
$14.78
24h Volume:
1.41M
Relative Volume:
0.89
Market Cap:
$974.46M
Revenue:
$796.00M
Net Income/Loss:
$-136.49M
P/E Ratio:
-7.00
EPS:
-2.09
Net Cash Flow:
$-64.24M
1W Performance:
-7.11%
1M Performance:
-27.65%
6M Performance:
-58.56%
1Y Performance:
-66.49%
1-Day Range:
$14.31
$14.98
1-Week Range:
$14.31
$16.30
52-Week Range:
$14.31
$47.60
Tandem Diabetes Care Inc Stock (TNDM) Company Profile
Name
Tandem Diabetes Care Inc
Sector
Industry
Phone
858-366-6900
Address
12400 HIGH BLUFF DRIVE, San Diego, CA
Compare TNDM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TNDM
Tandem Diabetes Care Inc
|
14.63 | 1.05B | 796.00M | -136.49M | -64.24M | -2.09 |
|
ABT
Abbott Laboratories
|
124.42 | 229.71B | 43.11B | 13.98B | 6.66B | 7.98 |
|
BSX
Boston Scientific Corp
|
103.78 | 154.35B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
387.32 | 149.60B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
89.70 | 114.97B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
76.56 | 45.92B | 5.54B | 4.18B | 623.10M | 7.00 |
Tandem Diabetes Care Inc Stock (TNDM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-09-25 | Downgrade | Citigroup | Neutral → Sell |
| Jun-16-25 | Initiated | Truist | Hold |
| Apr-10-25 | Initiated | Mizuho | Neutral |
| Mar-05-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-04-25 | Downgrade | Citigroup | Buy → Neutral |
| Mar-03-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-28-25 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-02-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-06-24 | Initiated | Bernstein | Outperform |
| Oct-04-24 | Initiated | Goldman | Neutral |
| Oct-02-24 | Initiated | RBC Capital Mkts | Outperform |
| Aug-22-24 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-08-24 | Initiated | Canaccord Genuity | Buy |
| May-30-24 | Initiated | Redburn Atlantic | Buy |
| May-22-24 | Upgrade | Citigroup | Neutral → Buy |
| Apr-29-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-25-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Mar-26-24 | Upgrade | Stifel | Hold → Buy |
| Aug-04-23 | Downgrade | Citigroup | Buy → Neutral |
| May-05-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Apr-24-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Mar-29-23 | Initiated | UBS | Neutral |
| Jan-26-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-15-22 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Aug-09-22 | Downgrade | Wells Fargo | Overweight → Underweight |
| Mar-02-22 | Resumed | BofA Securities | Neutral |
| Jan-19-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-21-21 | Resumed | Cowen | Outperform |
| May-25-21 | Initiated | Barclays | Underweight |
| Dec-15-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Aug-20-20 | Initiated | Wells Fargo | Overweight |
| Jul-31-20 | Upgrade | Guggenheim | Neutral → Buy |
| Jul-06-20 | Upgrade | Citigroup | Neutral → Buy |
| Jun-18-20 | Reiterated | Raymond James | Outperform |
| Apr-24-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Mar-23-20 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-05-20 | Initiated | Citigroup | Neutral |
| Feb-06-20 | Initiated | Raymond James | Outperform |
| Feb-04-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-18-19 | Initiated | Guggenheim | Buy |
| Oct-04-19 | Upgrade | UBS | Neutral → Buy |
| May-17-19 | Reiterated | BofA/Merrill | Neutral |
| May-13-19 | Initiated | SVB Leerink | Outperform |
| Mar-08-19 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-19 | Reiterated | BofA/Merrill | Neutral |
| Feb-27-19 | Reiterated | Lake Street | Buy |
| Nov-21-18 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Sep-26-18 | Reiterated | Dougherty & Company | Buy |
| Sep-26-18 | Reiterated | Piper Jaffray | Overweight |
View All
Tandem Diabetes Care Inc Stock (TNDM) Latest News
Is Tandem Diabetes Care Inc. a good long term investmentBreakthrough capital growth - Autocar Professional
What drives Tandem Diabetes Care Inc. stock priceRapidly growing investment returns - Autocar Professional
Down 27.0% in 4 Weeks, Here's Why You Should You Buy the Dip in Tandem Diabetes Care (TNDM) - Yahoo Finance
Wearable Injectors Market is expected to reach USD 24.99 billion - openPR.com
Digital Diabetes Management Market is projected to reach US$ - openPR.com
Diabetes Devices Market is projected to grow to US$ 64.8 billion - openPR.com
Tandem Diabetes Care Inc. Stock Analysis and ForecastFree Investment Portfolio Suggestions - Autocar Professional
What analysts say about Tandem Diabetes Care Inc. stockHigh-impact stock picks - jammulinksnews.com
Evolent Health, West Pharmaceutical Services, Myriad Genetics, Tandem Diabetes, and Integra LifeSciences Shares Are Falling, What You Need To Know - Yahoo Finance
Tandem Diabetes Care stock hits 52-week low at 14.86 USD - Investing.com
ContactThe Lethbridge HeraldNews and Sports from around Lethbridge - FinancialContent
Tandem Diabetes Care’s SWOT analysis: stock faces headwinds amid market shifts - Investing.com
Lacklustre Performance Is Driving Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) 27% Price Drop - simplywall.st
Artificial Intelligence Revolutionizing Early Detection of Diabetic Retinopathy Creating a Multi-Billion Dollar Revenue Opportunity - FinancialContent
What makes Tandem Diabetes Care Inc. stock price move sharplyFree Exclusive Investment Tips - beatles.ru
Tandem Diabetes Care Inc (TNDM) Shares Decline 3.49% on July 11 - AInvest
Tandem Diabetes, Solventum, LeMaitre, UFP Technologies, and Artivion Stocks Trade Down, What You Need To Know - Yahoo.co
Lacklustre Performance Is Driving Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) 28% Price Drop - 富途牛牛
Tandem Diabetes Care stock hits 52-week low at 15.34 USD By Investing.com - Investing.com South Africa
Tandem Diabetes Care stock hits 52-week low at 15.34 USD - Investing.com Nigeria
Tandem Diabetes Care Stock Downgraded to 'Sell' Amid Market ConcernsNews and Statistics - IndexBox
Why Tandem Diabetes (TNDM) Shares Are Sliding Today - TradingView
Tandem Diabetes Shares Drop Following Citi Downgrade Over Rising Competition - MSN
Citi adjusts MedTech outlook: Bullish on Haemonetics, bearish on Tandem Diabetes - Investing.com Canada
Citigroup Downgrades Tandem Diabetes Care to Sell From Neutral, Cuts Price Target to $14 From $24 - MarketScreener
Aehr Test Systems Posts Downbeat Sales, Joins RxSight, Vertical Aerospace And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
(TNDM) Trading Advice - news.stocktradersdaily.com
Further weakness as Tandem Diabetes Care (NASDAQ:TNDM) drops 10.0% this week, taking five-year losses to 83% - Yahoo Finance
CMS eyes competitive bidding for CGMs, insulin pumps - BioWorld MedTech
Tandem Diabetes Care to Announce Second Quarter 2025 Financial Results on August 6, 2025 - Business Wire
Why These Three Wearables Stocks Just Hit The Skids - Investor's Business Daily
Tandem Diabetes Care (NASDAQ:TNDM) Has Debt But No Earnings; Should You Worry? - simplywall.st
The 5 Most Interesting Analyst Questions From Tandem Diabetes’s Q1 Earnings Call - Yahoo Finance
ADA takeaways: Diabetes tech firms preview new patch pumps, glucose sensors - MedTech Dive
TNDM Stock Gains on t:slim X2's Compatibility With FreeStyle Libre 3 + - TradingView
Tandem Diabetes (TNDM) Expands Insulin Pump Features - GuruFocus
Tandem Diabetes Care Announces t:slim X2™ Insulin Pump Compatibility with Abbott’s FreeStyle Libre® 3 Plus Sensor in the United States | Daily Penny Alerts - FinancialContent
Abbott, Tandem Diabetes Care Partner For Glucose-Ketone Sensor for Diabetes Management - MSN
How To Trade (TNDM) - news.stocktradersdaily.com
Digital Diabetes Management Market 2025Growth in Apps, - openPR.com
Novel Diagnostic Technology Disrupting Diabetic Retinopathy Market Generating Billions in Revenue Opportunities - FinancialContent
What Does Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) Share Price Indicate? - Yahoo Finance
Tandem Diabetes Care’s SWOT analysis: stock faces growth hurdles amid market shifts - Investing.com UK
TNDM: Truist Securities Initiates Coverage with Hold Rating | TN - GuruFocus
TNDM: Truist Securities Initiates Coverage with Hold Rating | TNDM Stock News - GuruFocus
10 Best Stocks to Buy For Beginners Now - Insider Monkey
Truist bullish on diabetes companies citing potential market growth - Seeking Alpha
Truist initiates Tandem Diabetes Care stock with hold rating By Investing.com - Investing.com Canada
Tandem Diabetes Care Inc Stock (TNDM) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.15%
0.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):